Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells

Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current

(2015) Marta Gritti et al.   Oncotarget

Smarter drugs emerging in pancreatic cancer therapy

(2014) A. Kleger et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents

(2014) Minh Truong Do et al.   FREE RADICAL BIOLOGY AND MEDICINE

Trail Resistance Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness by Suppressing PTEN via miR-221 in Breast Cancer

(2014) Haiji Wang et al.   PLoS One

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

(2013) Wendy L. Bennett et al.   ANNALS OF INTERNAL MEDICINE

Elevation of miR-221 and -222 in the internal mammary arteries of diabetic subjects and normalization with metformin

(2013) Chasity B. Coleman et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Metabolic roles of AMPK and metformin in cancer cells

(2013) Yeon Kyung Choi et al.   MOLECULES AND CELLS

Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis

(2013) Zu-Yao Yang et al.   PLoS One

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

(2012) Francisco J. Esteva et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells

(2012) T Lu et al.   CANCER GENE THERAPY

Metformin and Cancer Stem Cells: Old Drug, New Targets

(2012) F. Bednar et al.   Cancer Prevention Research

Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation

(2012) Arron Sikka et al.   CELL CYCLE

Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells

(2012) Weiguang Li et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells

(2011) B. Bao et al.   Cancer Prevention Research

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin: A Therapeutic Opportunity in Breast Cancer

(2010) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

A phase I study of temsirolimus and metformin in advanced solid tumours

(2010) Mary J. MacKenzie et al.   INVESTIGATIONAL NEW DRUGS

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes

(2009) G. Libby et al.   DIABETES CARE

Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma

(2009) Jong-Kook Park et al.   PANCREAS

MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer

(2008) M Garofalo et al.   ONCOGENE

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

(2008) I Ben Sahra et al.   ONCOGENE